Fold change of mRNA levels of selected genes in DC after exposure to DD in vivo and in vitro and of controls
| Gene . | mDC1 (DD in vivo) . | Monocytes (DD in vivo) . | maDC+DD (48 h, in vitro) . | imDC+MC (12 h, in vitro) . | imDC+ LPS (12 h, in vitro) . |
|---|---|---|---|---|---|
| Tolerance/Th2 markers | |||||
| Stat3 | 5.68 | 3.80 | 57.32 | nc | nc |
| β-Catenin | 5.46 | nc | nc | 2.63 | nc |
| NOD2 | 6.94 | nc | nc | nc | nc |
| MHC complex | |||||
| CIITA | 10.17 | 16.36 | 10.42 | 0.31 | nc |
| HLA-A | 4.02 | 5.67 | 0.18 | nc | nc |
| HLA-B | 4.52 | 4.19 | nc | nc | nc |
| HLA-C | 4.25 | 6.26 | 0.18 | nc | nc |
| HLA-E | 4.29 | 6.59 | 0.15 | nc | nc |
| HLA-DMA | 4.3 | nc | nc | nc | nc |
| HLA-DMB | 6.14 | nc | 16.5 | 0.28 | 0.38 |
| HLA-DRB4 | Nc | 8.5 | nc | nc | nc |
| HLA-DRB5 | Nc | 6.9 | nc | nc | nc |
| HLA-DQB1 | Nc | 5.23 | nc | nc | nc |
| HLA-DQA2 | Nc | 4.25 | 14.9 | nc | nc |
| HLA-DBP1 | 5.14 | 13.12 | nc | nc | nc |
| HLA-DPA1 | Nc | 11.77 | nc | nc | nc |
| PSME1 | 4.81 | nc | nc | nc | nc |
| PSME2 | 7.32 | nc | nc | nc | nc |
| TAPBP | 4.02 | 9.23 | nc | nc | nc |
| B2M | 3.8 | 6.02 | 7.13 | nc | nc |
| Coreceptors | |||||
| CD80 | Nc | nc | nc | 11.65 | 5.88 |
| CD86 | Nc | nc | nc | 2.84 | nc |
| CD83 | Nc | nc | nc | 4.38 | nc |
| CD40 | Nc | nc | 0.08 | nc | nc |
| Gene . | mDC1 (DD in vivo) . | Monocytes (DD in vivo) . | maDC+DD (48 h, in vitro) . | imDC+MC (12 h, in vitro) . | imDC+ LPS (12 h, in vitro) . |
|---|---|---|---|---|---|
| Tolerance/Th2 markers | |||||
| Stat3 | 5.68 | 3.80 | 57.32 | nc | nc |
| β-Catenin | 5.46 | nc | nc | 2.63 | nc |
| NOD2 | 6.94 | nc | nc | nc | nc |
| MHC complex | |||||
| CIITA | 10.17 | 16.36 | 10.42 | 0.31 | nc |
| HLA-A | 4.02 | 5.67 | 0.18 | nc | nc |
| HLA-B | 4.52 | 4.19 | nc | nc | nc |
| HLA-C | 4.25 | 6.26 | 0.18 | nc | nc |
| HLA-E | 4.29 | 6.59 | 0.15 | nc | nc |
| HLA-DMA | 4.3 | nc | nc | nc | nc |
| HLA-DMB | 6.14 | nc | 16.5 | 0.28 | 0.38 |
| HLA-DRB4 | Nc | 8.5 | nc | nc | nc |
| HLA-DRB5 | Nc | 6.9 | nc | nc | nc |
| HLA-DQB1 | Nc | 5.23 | nc | nc | nc |
| HLA-DQA2 | Nc | 4.25 | 14.9 | nc | nc |
| HLA-DBP1 | 5.14 | 13.12 | nc | nc | nc |
| HLA-DPA1 | Nc | 11.77 | nc | nc | nc |
| PSME1 | 4.81 | nc | nc | nc | nc |
| PSME2 | 7.32 | nc | nc | nc | nc |
| TAPBP | 4.02 | 9.23 | nc | nc | nc |
| B2M | 3.8 | 6.02 | 7.13 | nc | nc |
| Coreceptors | |||||
| CD80 | Nc | nc | nc | 11.65 | 5.88 |
| CD86 | Nc | nc | nc | 2.84 | nc |
| CD83 | Nc | nc | nc | 4.38 | nc |
| CD40 | Nc | nc | 0.08 | nc | nc |
Monocytes and mDC1: were obtained by FACS sorting before (day 0) and during (day 2) DD treatment (supplemental Figure 7A). Numbers in these rows represent fold mRNA change (mean values of 2 patients) after 2 DD infusions (12 μg/kg) (day 2). maDC+DD: prepared from 2 healthy donors and treated with 100 ng/mL of DD for 48 hours (supplemental Figure 7B). Numbers represent fold mRNA change (mean values of triplicates) with respect to an untreated control of the same individual. imDC+MC; imDC+LPS: existing data sets of maturing DCs stimulated by a conventional maturation cocktail (MC; see “Materials and methods”) (12-hour exposure) or LPS (12 hours). Numbers represent fold mRNA changes with respect to an untreated control. nc results may be at odds with published or expected data (eg, upregulation of Stat3 after LPS treatment), as this could be the result of the sampling time point (12 hours) or arise from technical reasons, like the noise in the microarray platform, causing statistics to filter out genes that are otherwise known to be there and/or upregulated.
h, hours; nc, no change.